Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
androgen receptor
early breast cancer
immunohistochemistry
progesterone receptor negative
relapse-free survival
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
04
2020
accepted:
19
08
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
Progesterone receptor (PgR) negative breast cancer (BC) is an aggressive subtype with poor prognosis and reduced response to endocrine treatments. Several studies have suggested that androgen receptor (AR) expression is associated with a favorable tumor biology, longer recurrence free survival (RFS), and overall survival. In the literature no data exist regarding the role of AR expression in early stage estrogen receptor (ER)+/PgR- BCs. The aim of this study was to evaluate the prognostic role of AR expression in this setting. This is a monocentric retrospective study in which 208 patients who underwent surgical intervention for ER+/PgR-/Human Epidermal growth factor Receptor 2 (HER2)- BC were included. The primary objective was to analyze the relationship between AR expression and RFS. At a median follow-up of 77 months, 75 patients (36%) had a disease relapse (all sites included). AR expression was significantly higher in patients who did not relapse compared with those who relapsed with an impact on RFS (hazard ratio [HR] = 0.99, The results of this study support the potential prognostic role of AR in patients with ER+/PgR- BCs and may contribute to the identification of subgroups of high-risk patients.
Sections du résumé
BACKGROUND
BACKGROUND
Progesterone receptor (PgR) negative breast cancer (BC) is an aggressive subtype with poor prognosis and reduced response to endocrine treatments. Several studies have suggested that androgen receptor (AR) expression is associated with a favorable tumor biology, longer recurrence free survival (RFS), and overall survival. In the literature no data exist regarding the role of AR expression in early stage estrogen receptor (ER)+/PgR- BCs. The aim of this study was to evaluate the prognostic role of AR expression in this setting.
PATIENTS AND METHODS
METHODS
This is a monocentric retrospective study in which 208 patients who underwent surgical intervention for ER+/PgR-/Human Epidermal growth factor Receptor 2 (HER2)- BC were included. The primary objective was to analyze the relationship between AR expression and RFS.
RESULTS
RESULTS
At a median follow-up of 77 months, 75 patients (36%) had a disease relapse (all sites included). AR expression was significantly higher in patients who did not relapse compared with those who relapsed with an impact on RFS (hazard ratio [HR] = 0.99,
CONCLUSIONS
CONCLUSIONS
The results of this study support the potential prognostic role of AR in patients with ER+/PgR- BCs and may contribute to the identification of subgroups of high-risk patients.
Identifiants
pubmed: 32994808
doi: 10.1177/1758835920958355
pii: 10.1177_1758835920958355
pmc: PMC7502860
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920958355Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Breast Cancer Res. 2019 Feb 22;21(1):30
pubmed: 30795773
Breast Cancer Res. 2014 Jan 22;16(1):R7
pubmed: 24451109
Endocr Relat Cancer. 2020 Apr;27(4):199-208
pubmed: 31958314
BMC Cancer. 2015 Mar 18;15:138
pubmed: 25880075
Clin Cancer Res. 2017 Jun 1;23(11):2702-2712
pubmed: 28151718
Front Endocrinol (Lausanne). 2018 Aug 28;9:492
pubmed: 30210453
J Clin Oncol. 2013 Jan 10;31(2):203-9
pubmed: 23233704
Endocr Relat Cancer. 2018 Mar;25(3):163-172
pubmed: 29386247
Cancer Treat Rev. 2017 Dec;61:15-22
pubmed: 29078133
J Clin Oncol. 2005 Oct 10;23(29):7350-60
pubmed: 16145060
Cancers (Basel). 2019 Aug 24;11(9):
pubmed: 31450618
Mol Cell Endocrinol. 2012 Jun 24;357(1-2):71-9
pubmed: 21945473
J Clin Oncol. 2009 Jun 20;27(18):2938-45
pubmed: 19364964
J Clin Oncol. 2014 Sep 1;32(25):2794-803
pubmed: 25049332
J Clin Oncol. 2007 Oct 20;25(30):4772-8
pubmed: 17876012
Cancer Chemother Pharmacol. 2019 Sep;84(3):609-620
pubmed: 31297554
J Natl Cancer Inst. 2014 Jan;106(1):djt319
pubmed: 24273215
J Clin Oncol. 2003 May 15;21(10):1973-9
pubmed: 12743151
Ann Oncol. 2017 Oct 1;28(10):2420-2428
pubmed: 28961844
Breast Cancer Res Treat. 2010 Dec;124(3):607-17
pubmed: 20127405
J Clin Oncol. 2011 Sep 1;29(25):3351-7
pubmed: 21788566
Br J Cancer. 2014 Feb 4;110(3):565-72
pubmed: 24300977
Br J Cancer. 2019 Dec;121(12):1009-1015
pubmed: 31728025
Endocr Relat Cancer. 2014 Aug;21(4):T161-81
pubmed: 24951107
Mod Pathol. 2011 Jul;24(7):924-31
pubmed: 21552212
Mol Cell Endocrinol. 2012 Jun 24;357(1-2):4-17
pubmed: 22193050
BMC Cancer. 2012 Apr 02;12:132
pubmed: 22471922
Mol Cell Endocrinol. 2018 May 5;466:2-14
pubmed: 28851667
Medicina (B Aires). 2019;79(Spec 6/1):540-545
pubmed: 31864223
BMC Cancer. 2018 Mar 27;18(1):348
pubmed: 29587674
Onco Targets Ther. 2016 Mar 21;9:1707-13
pubmed: 27051305
Br J Cancer. 2018 Nov;119(11):1316-1325
pubmed: 30410061
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Trends Cancer. 2016 Jan;2(1):35-48
pubmed: 28741499
J Cancer Res Clin Oncol. 2017 Dec;143(12):2505-2509
pubmed: 28889189
Breast Cancer Res Treat. 2018 Nov;172(2):283-296
pubmed: 30109519
Breast Cancer Res. 2007;9(1):R6
pubmed: 17239243
PLoS One. 2013 Dec 04;8(12):e82650
pubmed: 24324816